Cero Therapeutics Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
CERO Therapeutics reported a significant increase in net loss for Q3 2025, faced Nasdaq delisting, and continues to rely on further capital raises to fund its early-stage clinical development.
OQB
CERO Therapeutics reported a significantly wider net loss for Q2 2025, driven by deemed dividends, while making progress in its AML and NSCLC/ovarian cancer clinical programs and securing additional financing.
OQB
CERO Therapeutics Holdings, Inc. announces its financial results for the quarter ended March 31, 2025, highlighting advancements in its lead drug candidate, CER-1236, and recent capital raising activities.
OQB
CERo Therapeutics Holdings has filed an amendment to its quarterly report for the period ended September 30, 2024, solely to include Inline Extensible Business Reporting Language (iXBRL) data tagging.
OQB
10-Q: CERO Therapeutics Reports Q3 2024 Results, Navigates Regulatory Hurdles and Financial Restructuring
CERO Therapeutics reported its Q3 2024 financial results, highlighting increased operating expenses, a net loss, and ongoing efforts to address a clinical hold on its lead drug candidate, while also navigating Nasdaq listing compliance issues.
OQB
CERo Therapeutics Holdings, Inc. released its second quarter 2024 financial results, highlighting increased R&D spending, a net loss, and updates on its IND submission and Nasdaq listing compliance.
OQB
CERo Therapeutics Holdings reports its first quarterly results post-merger, highlighting a net loss and increased operating expenses, alongside a significant gain from derivative liabilities.